Jonathan Brammer
Clinical trials sponsored by Jonathan Brammer, explained in plain language.
-
New hope: drug may stop lymphoma relapse after transplant
Disease control Recruiting nowThis study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body…
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New pill trial targets rare leukemia
Disease control Recruiting nowThis study is testing whether a pill called ruxolitinib can shrink tumors in adults with a rare blood cancer called T-cell large granular lymphocyte leukemia (T-LGLL). The drug works by blocking enzymes that cancer cells need to grow. Researchers will enroll 30 patients to see ho…
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC